

July 30, 2021

**BSE Limited**  
1<sup>st</sup> Floor,  
P J Towers,  
Dalal Street,  
Mumbai-400001

**Code: 532321**

**National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051

**Code: Cadilahc**

**Re.:** Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated July 30, 2021 titled “Zydus Cadila receives final approval from USFDA for Fulvestrant Injection”.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**

  
**DHAIVAL N. SONI**  
**COMPANY SECRETARY**



**Encl.:** As above

## Zydus Cadila receives final approval from USFDA for Fulvestrant Injection

Ahmedabad, India, 30 July, 2021

Zydus Cadila has received final approval from the USFDA to market Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Pre-filled Syringe (USRLD: Faslodex Injection). Fulvestrant injection is used alone or in combination with other drugs to treat a certain type of hormone receptor positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body in women who have experienced menopause.

The drug will be manufactured at the group's formulation manufacturing facility at the Zydus Biologics, Ahmedabad. The group now has 320 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

### About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

\*\*\*